openPR Logo
Press release

Biologics Market :Technological Advancements, Evolving Industry Trends and Insights 2024

03-10-2017 08:33 PM CET | Health & Medicine

Press release from: Transparency Market Research – Pharmaceutical

Biologics Market :Technological Advancements, Evolving

Vast Growth Opportunities in Asia Pacific to Bring in More Investment

Geographically, the global biologics market is segmented into North America, Europe, Latin America, Asia-Pacific, and Middle East and Africa. North America is presently the dominant regional market, holding a share of over 40% in the global market. The region is expected to continue its dominance in terms of revenue contribution to the global market, expected to account for over 40% by 2024 as well.

However, the biologics market in Asia Pacific is expected to emerge as the most attractive regional market, exhibiting a massive 15.6% CAGR from 2016 through 2024. By the end of the forecast period, the region is expected to replace Europe and become the second most profitable region for biologics.

Owing to the presence of an enormous patient-base and low costs of raw material and manufacturing, an increased number of multi-national pharmaceutical companies are expanding their manufacturing and sales capacities in Asia Pacific. Changes in the regulatory scenario in Asia Pacific are also expected to attract many foreign investors in the Asian markets in the next few years. As a result, the biologics market in Asia Pacific is expected to witness highly positive growth in the next few years.

The highly fragmented global market for biologics features the presence of a large number of international pharmaceutical companies and many domestic players. Some of the key vendors in the market are AstraZeneca, AbbVie Inc., Amgen Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Johnson & Johnson Services, Inc., GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Novartis AG, and Sanofi.

Global Biologics Market: Snapshot

The global pharmaceutical industry has charted growth at an impressive rate in the past few years owing to a vast increase in research and developmental activities, development and launch of new product varieties, breakthrough progress in treatment options for chronic and rare diseases. A significant rise in big pharmaceutical companies’ operational setups and funds directed towards novel and more effective drug varieties for complex diseases has also been observed across the globe in the past few years. The scenario has led to an increased focus on the development of biologics and a large number of international players are venturing into the global biologics market.

Transparency Market Research estimates that the market will tread along a healthy growth path in the next few years. The market is anticipated to exhibit a CAGR of about 10.9% over the period between 2016 and 2024. If the number holds true, the market is expected to rise to a valuation of US$479, 752 mn by 2024.

Browse full report on Biologics Market -

http://www.transparencymarketresearch.com/global-biologics-market.html

Monoclonal Antibodies to Remain Most Profitable Product Variety

The global biologics market is segmented on the basis of product type into monoclonal antibodies, vaccines, recombinant hormones/vaccines, cell therapy, gene therapy and other products. Monoclonal antibodies segment is anticipated to dominate the market throughout the forecast period; the segment is expected to stand for an annual share of 46% by 2024 and expand at a favorable 11.9% CAGR over the period between 2016 and 2024.

The segments of vaccines and recombinant hormones/proteins are also expected to attractive for manufacturers, although growth of these segments will be relatively stationary over the forecast period. The segment of vaccines will exhibit a slight decline by 2024, chiefly owing to the lower pricing of most vaccines and many key contenders on the verge of going off patent in the developed market. The segment of recombinant hormones/proteins will witness a slight rise in its share in the global market by 2024 owing to sustainable sales in developed and emerging markets.

Global Biologics Market: Scope and Methodology

This report provides forecast and analysis of the global biologics market on the global and regional levels. It provides historical data of 2015 along with forecast from 2016 to 2024 in terms of revenue (US$ Mn). The report also includes macroeconomic indicators along with an outlook for biologics revenue annually. It includes drivers and restraints of the global biologics market and their impact on each region during the forecast period. The report also comprises the study of applications and opportunities for biologics manufacturers. It also includes a detailed analysis by product type and supply chain analysis with a list of suppliers and industry stakeholders at each node in the supply chain.

In order to provide users of this report with a comprehensive view of the market, we have included detailed competitiveness analysis, key blockbuster products, clinical pipeline analysis and company players with unique propositions. The dashboard provides a comprehensive comparison of biologics manufacturers on parameters such as revenue sales, ranking of global players, strategic consolidations, i.e. mergers & acquisitions, licensing activities, as well as R&D activities. The study encompasses market attractiveness analysis, product type, application type, and region.

Request for sample of this report -

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=15509

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biologics Market :Technological Advancements, Evolving Industry Trends and Insights 2024 here

News-ID: 465620 • Views: 532

More Releases from Transparency Market Research – Pharmaceutical

Plasma Protease C1-inhibitor Treatment Market Estimated to Flourish by 2025
A fresh market intelligence study by Transparency Market Research (TMR) states that the business landscape of the global plasma protease c1-inhibitor treatment market is consolidated with intense competitive rivalry among leading players. TMR detects Shire plc led the global plasma protease C1-inhibitor treatment market in 2016. Key factors that account for its dominance are expanded product portfolio, acquisitions, and widespread market presence. Pharming Group N.V., CSL Limited, and Sanquin are
Narcolepsy Market - Global Industry Trends and Forecast - 2019
Narcolepsy is a chronic neurological disorder, which is characterized by brain’s inability to control the sleep-wake cycle of an individual. This disorder is not caused due to any mental illness, but is mainly caused due to genetic abnormalities occurring from environmental factors or biologic factors. Narcoleptic individuals exhibita typical characteristic symptom, i.e. excessive daytime sleepiness (EDS), where individuals experience disturbed night sleep and abnormal daytime sleep pattern. Narcolepsy disorder is
Diabetic Macular Edema Market - Key Growth Factors and Forecast 2019
Macular edema is the condition when the fluid and proteins start collecting on or under the macula of the eye thereby resulting in swelling. Due to such swelling, a person’s central eye vision gets distorted. Macular edema is classified into two types namely cystoids macular edema (CME) and diabetic macular edema (DME). Obtain Report Details @ http://www.transparencymarketresearch.com/diabetic-macular-edema-market.html Diabetic macular edema is the major reason for loss of vision in patients
Primary Systemic Amyloidosis Market- Get Facts About Business Strategies and Fin …
Amyloids are the substance made up of abnormally formed protein in the bone marrow that gets saturated in different tissues or organs of the body. The condition is termed as amyloidosis. There are various types of amyloidosis out of which primary systemic amyloidosis are most common, these are associated with plasma cell dyscrasia and has no historical evidence of disease. Kidney, intestines, liver, heart and nerves are the common organs

All 5 Releases


More Releases for Asia

Asia IVD Market
According to a new report published by Allied Market Research, the Asia Pacific In-vitro diagnostics market was valued at $12.9 billion in 2015, and is expected to reach $19.0 billion registering a CAGR of 5.6% during 2016 to 2022. The report offers a detailed analysis of the key segments, top investment pockets, changing dynamics, market size & estimations, and competitive scenario. Download Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/1256 The Asia-Pacific IVD market is
RAMPF Korea – Producing in Asia for Asia
Joint Venture for the Asian markets – The international RAMPF Group has realigned the cooperation with its long-standing partner Orient Dosiertechnik from Korea with the founding of RAMPF Korea Co., Ltd. The new company based in Hwaseong City is developing and producing mixing and dispensing systems specifically for the Asian markets. Within the framework of the new joint venture based in Hwaseong City, mixing and dispensing systems are being developed and
LIXIL Asia Presents Asia Pacific Property Awards
Through its power brands GROHE and American Standard, LIXIL Asia signs a three-year deal to become the Headline Sponsor of the Asia Pacific Property Awards from 2019 until 2022. 23rd January 2019: The International Property Awards, first established in 1993, are open to residential and commercial property professionals from around the globe. They celebrate the highest levels of achievement by companies operating within the architecture, interior design, real estate and property
MES: Expansion in Asia
Berlin, November 24, 2014: Model Engineering Solutions (MES), the Berlin-based specialist for model-based software development, has significantly expanded its business in Asia. In recent years, MES has built up a network of local partners in Japan, Korea, China, and India in order to benefit from the growing market and increasing interest in model-based development and ISO 26262 in Asia. Asia: Driving force in the automotive industry The automotive industry continues
Undersea Defence Technology Asia, UDT Asia 2011
Latest Military Diving Technologies featured in UDT Asia Equipping Asia’s navies with the latest diving technology for asymmetric warfare and operations SINGAPORE, 17 October 2011 - Naval diving and underwater special operations is a field that is seeing increased attention and investment amongst navies in Asia. Units such as the Indonesian Navy‟s KOPASKA, the Republic of Singapore Navy‟s Naval Diving Unit (NDU), the Royal Malaysian Navy‟s PASKAL are increasingly utilising specialised equipment for conducting
UDT Asia 2011
Clarion Events hosts the Undersea Defence Technology (UDT) Asia 2011 conference and exhibition to bring senior naval and industry personnel together to cover underwater developments in the region Singapore, May 30 – Clarion Events is hosting UDT Asia on 30 November – 1 December 2011. The event brings together the undersea defence community in Asia, featuring top regional naval speakers, who will be addressing the latest underwater requirements for Asian navies. According